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Abstract 
Background: The preoperative neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) are 
associated with poor prognosis of gastric cancer. We aimed to determine whether the combination of NLR and PLR 
(NLR–PLR) could better predict survival of patients after curative resection for stage I–II gastric cancer.
Methods: We collected data from the medical records of patients with stage I–II gastric cancer undergoing curative 
resection between December 2000 and November 2012 at the Sun Yat-sen Cancer Center. The preoperative NLR–
PLR was calculated as follows: patients with both elevated NLR (≥2.1) and PLR (≥120) were given a score of 2, and 
patients with only one or neither were given a score of 1 or 0, respectively.
Results: Kaplan–Meier analysis and log-rank tests revealed significant differences in overall survival (OS) among 
patients with NLR–PLR scores of 0, 1 and 2 (P < 0.001). Multivariate analysis showed that OS was independently 
associated with the NLR–PLR score [hazard ratio (HR) = 1.51, 95% confidence interval (CI) 1.02–2.24, P = 0.039] and 
TNM stage (HR = 1.36, 95% CI 1.01–1.83, P = 0.041). However, other systemic inflammation-based prognostic scores, 
including the modified Glasgow prognostic score, the prognostic nutritional index, and the combination of platelet 
count and NLR, were not. In TNM stage-stratified analysis, the prognostic significance of NLR–PLR was maintained 
in patients with stage I (P < 0.001) and stage II cancers (P = 0.022). In addition, the area under the receiver operating 
characteristic curve for the NLR–PLR score was higher than those of other systemic inflammation-based prognostic 
scores (P = 0.001).
Conclusion: The preoperative NLR-PLR score is a useful predictor of postoperative survival in the patients with stage 
I–II gastric cancer and may help identify high-risk patients for rational therapy and timely follow-up.
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Background
Gastric cancer is the second leading cause of cancer-
related death worldwide, with approximately 1 million new 
cases diagnosed annually [1, 2]. Despite advancements in 
surgical techniques and adjuvant chemotherapy, the post-
operative overall survival (OS) of gastric cancer patients is 
still short, given the relatively late stage of disease at diag-
nosis [3, 4]. Identifying prognostic factors of OS may help 
identify patients at high risk for close follow-up and guide 
treatment for selected patients.
A systemic inflammatory response is important in car-
cinogenesis and tumor progression and is associated with 
short postoperative survival in patients with various types 
of cancer [5–8]. Several systemic inflammation-based 
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scores such as the neutrophil-to-lymphocyte ratio (NLR), 
platelet-to-lymphocyte ratio (PLR), modified glasgow 
prognostic score (mGPS), prognostic nutritional index 
(PNI), and the combination of platelet count (PLT) and 
NLR (PLT–NLR) have prognostic values in many types 
of cancer, including gastric cancer [9–13]. A study from 
our center found that an elevated preoperative GPS was 
superior to NLR and PLR for predicting prognosis of 
the patients with stage III gastric cancer [14]. However, 
appropriate predictors for stage I–II gastric cancers 
remain unclear. The patients with stage I–II gastric can-
cer have a relatively good prognosis, but recurrence or 
metastasis is often difficult to predict in such patients. 
Therefore, a preoperative predictor of postoperative sur-
vival in the patients with stage I–II gastric cancer would 
be useful.
To test our hypothesis that an integrated indicator may 
better reflect the balance of host inflammation, we deter-
mined the prognostic value of NLR–PLR in predicting 
postoperative survival of the patients with stage I–II gas-
tric cancer.
Patients and methods
The study was approved by the Ethical Committee of Sun 
Yat-sen University Cancer Center and complied with the 
standards of the Declaration of Helsinki.
Patient selection
Data were collected from the records of patients with 
gastric cancer undergoing curative resection (D2 lym-
phadenectomy) between December 2000 and November 
2012 at the Sun Yat-sen University Cancer Center. The 
diagnosis of gastric cancer was confirmed pathologically 
with postoperative histological specimens, and clinical 
stage was determined as I or II according to the Ameri-
can Joint Committee on Cancer tumor-nodes-metastasis 
(TNM) staging system [15]. The patients who had inflam-
matory diseases for nearly 1 month and those who died of 
non-cancer-related causes were excluded from the study. 
The patients undergoing neoadjuvant chemotherapy or 
radiotherapy were also excluded. We collected data on 
age, sex, preoperative laboratory examinations, postoper-
ative tumor characteristics, and survival duration. Blood 
samples taken within 1 week before surgery were tested 
for concentrations of C-reactive protein (CRP) and albu-
min and for lymphocyte, neutrophil, and platelet counts.
Follow‑up
After surgery, all patients were followed regularly every 
6  months for the first 2  years and every year thereafter 
with laboratory tests and dynamic computed tomography 
(CT) and gastroscopy. The last follow-up date was July 8, 
2014. Survival duration was measured from the date of 
surgery until death or last follow-up.
Inflammation‑based scores
The NLR was defined as the absolute neutrophil count 
divided by the absolute lymphocyte count. Similarly, the 
PLR was defined as the absolute platelet count divided by 
the absolute lymphocyte count.
The mGPS was calculated as previously described [11]: 
patients were given an mGPS score of 2 if they had a CRP 
concentration greater than 10 mg/L and an albumin con-
centration less than 35  g/L; an mGPS score of 1 if they 
had a CRP concentration greater than 10  mg/L and an 
albumin concentration of 35 g/L or higher; and an mGPS 
of 0 if they had a CRP concentration of 10 mg/L or less.
The PNI was calculated from the serum albumin con-
centration and absolute lymphocyte count: the patients 
in whom a combined albumin (g/L) ×  total lymphocyte 
count (×109/L) was 45 or higher were assigned a PNI 
score of 0; the patients with a count less than 45 were 
assigned a score of 1 [12].
The PLT–NLR was assigned as follows: the patients with 
an elevated PLT (>300 × 109/L) and an elevated NLR (>3) 
were assigned a score of 2; the patients with one abnormal 
value were assigned a score of 1; and the patients with no 
abnormal values were assigned a score of 0 [13].
The NLR–PLR was calculated as follows: the patients 
with both an elevated NLR (≥2.1) and PLR (≥120) were 
assigned a score of 2; the patients with only one elevated 
value were assigned a score of 1; the patients with no ele-
vated values were assigned a score of 0.
Statistical methods
Data are reported as means and 95% confidence intervals 
(CI). The relationships between the inflammation-based 
scores and the clinicopathologic characteristics were 
analyzed with the Pearson Chi square test. Correlation 
between NLR and PLR was assessed with Pearson’s cor-
relation coefficient. Kaplan–Meier analysis and log-rank 
test were used to compare postoperative survival among 
groups with different NLR–PLR scores. Continuous vari-
ables meeting the assumption of linearity in the logit 
were categorized by the optimal cutoff value as deter-
mined by receiver operating characteristic (ROC) curve 
analyses.
Covariates significant in univariate analysis at the 0.05 
level and not significantly associated with others were 
included in a Cox proportional hazard model for the final 
multivariate analysis. The prognostic value of the sys-
temic inflammation-based prognostic scores was com-
pared using the ROC analyses. Alpha was set at 0.05, and 
all data were analyzed with the SPSS 19.0 statistical soft-
ware program (IBM Corporation, Armonk, NY, USA).
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Results
Patient characteristics
Of the 305 patients enrolled, 168 (55.1%) were men, and 
137 (44.9%) were women (Table 1). The median age was 
57  years (range, 19–89  years). The median follow-up 
duration was 61  months (range, 1–162  months). Before 
2005, CRP was not tested regularly in our center. There-
fore, 90 patients were not tested for CRP, and we lacked 
associated data for mGPS. By July 8, 2014, 70 (23.0%) 
patients died, and 235 (77.0%) were still alive. The median 
OS was not approached. The 3- and 5-year OS rates 
were 84.9% and 79.7%. The NLR-PLR score was 0 for 120 
patients, 1 for 96 patients, and 2 for 89 patients.
Selection of optimal cutoff values
According to the results of ROC analysis (Fig.  1), the 
patients were categorized into two groups by the opti-
mal cutoff values of NLR (low, <2.1; high, ≥2.1) and PLR 
(low,  <120; high,  ≥120). Moreover, NLR was positively 
correlated with PLR (r = 0.37, P < 0.001).
Survival and prognostic factors
An NLR–PLR score of 2 was associated with older age 
(P  =  0.026), tumor location in the upper third of the 
stomach (P  =  0.029), larger tumor size (P  <  0.001), 
higher TNM stage (P  =  0.034), higher mGPS score 
(P < 0.001), higher PNI score (P < 0.001), and high PLT-
NLR (P < 0.001; Table 2). The mean OS was significantly 
longer for the patients with a NLR–PLR score of 0 than 
for the patients with scores of 1 or 2 (142.2 vs. 119.0 and 
110.9  months; P  <  0.001). Of note, the mean OS was 
shorter in stage I patients with an NLR–PLR score of 2 
(89.4 months) than in stage II patients with an NLR–PLR 
score of 0 (127.3  months), although the difference was 
not significant (P  =  0.074). The 5-year OS rates of the 
patients with NLR-PLR scores of 0, 1, and 2 were 90.5%, 
73.8%, and 64.0%, respectively (P < 0.001; Fig. 2a).
Univariate and multivariate analyses were performed 
to assess the relationship between clinical characteris-
tics and OS (Table 3). Multivariate analyses showed that 
OS was independently associated with the NLR–PLR 
score (HR  =  1.51, 95% CI  1.02–2.24, P  =  0.039) and 
TNM stage (HR =  1.36, 95% CI  1.01–1.83, P =  0.041). 
Table 1 Clinical and  laboratory characteristics as  well 
as  overall survival of  the 305 patients with  stage I–II gas-
tric cancer after resection
mGPS modified glasgow prognostic score, PNI prognostic nutritional index, PLT 
platelet count, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte 
ratio
a The median survival for most groups was not arrived because most patients 
were still alive at the last follow-up. Therefore, survival data are presented as 
mean with the 95% confidence interval (CI) in parentheses
b Kaplan–Meier survival analysis
c Before 2005, CRP was not tested regularly in our center. Therefore, CRP data 
are not available for 90 patients, and we lacked associated data for mGPS




 <60 years 168 (55.1) 132.6 (123.7–141.5)
 ≥60 years 137 (44.9) 110.5 (98.2–122.9)
Sex 0.072
 Male 202 (66.2) 115.7 (105.6–125.8)
 Female 103 (33.8) 135.0 (123.7–146.3)
Tumor location in the stomach <0.001
 Upper third 87 (28.5) 82.0 (70.6–93.4)
 Middle third 59 (19.3) 131.7 (116.4–147.1)
 Lower third 159 (52.1) 133.3 (123.3–143.3)
Tumor size 0.343
 <3 cm 156 (51.1) 123.3 (112.8–133.9)
 ≥3 cm 149 (48.9) 121.5 (110.4–132.6)
TNM stage 0.001
 IA 56 (18.4) 108.1 (102.4–113.8)
 IB 53 (17.4) 112.9 (100.5–125.3)
 IIA 50 (16.4) 115.9 (98.2–133.6)
 IIB 146 (47.9) 111.1 (99.0–123.2)
mGPSc <0.001
 0 158 (51.8) 75.1 (70.5–79.6)
 1 44 (14.4) 67.4 (58.9–75.9)
 2 13 (4.3) 42.7 (25.8–59.6)
PNI 0.010
 0 282 (92.5) 126.7 (118.8–134.7)
 1 23 (7.5) 68.5 (49.7–87.4)
PLT–NLR 0.009
 0 210 (68.9) 128.3 (119.9–136.7)
 1 78 (25.6) 93.7 (79.5–107.8)
 2 17 (5.6) 125.3 (96.2–154.4)
NLR–PLR <0.001
 0 120 (39.3) 142.2 (133.7–150.8)
 1 96 (31.5) 119.0 (105.5–132.5)
 2 89 (29.2) 100.9 (85.4–116.4)
Fig. 1 Receiver operating characteristic curve for the a neutrophil-
to-lymphocyte ratio (NLR) and b platelet-to-lymphocyte ratio (PLR). 
Arrows indicate optimal cutoff values
Page 4 of 7Sun et al. Chin J Cancer  (2016) 35:57 
When stratified by TNM stage, the prognostic value of 
NLR–PLR scores remained in the patients with stage I 
(P < 0.001; Fig. 2b) and stage II gastric cancer (P = 0.022; 
Fig. 2c).
Comparison between inflammation‑based scores
To further evaluate the prognostic values of the systemic 
inflammation-based prognostic scores, ROC analysis was 
performed, and AUC values were compared (Fig. 3). The 
NLR–PLR score had a higher AUC value (0.66; P = 0.001) 
than mGPS, PNI, and PLT–NLR (Table 4).
Discussion
Accumulating evidence indicates that a systemic inflam-
matory response is associated with a poor outcome in 
many types of cancer [16–19]. In our study, we deter-
mined the prognostic value of the NLR–PLR score in the 
patients with stage I–II gastric cancer. We found that the 
score independently predicted OS in these patients bet-
ter than other inflammation-based prognostic scores we 
tested.
Cancer and inflammation are linked [20, 21]. However, 
the mechanisms by which inflammatory response induces 
a poor outcome are still ambiguous and poorly understood. 
Several mechanisms have been proposed. First, the tumor 
microenvironment inhabited by inflammatory cells is cru-
cial in carcinogenesis, promoting tumor cell proliferation 
and migration [22, 23]. Second, tumor cells themselves 
and tumor-associated leukocytes could produce various 
inflammatory cytokines, such as tumor necrosis factor-
alpha, interleukin-6, and vascular endothelial growth fac-
tor. These inflammatory cytokines and chemokines have 
powerful effects on cancer growth, invasion, and metas-
tasis [24]. Third, cancer-related inflammation can recruit 
regulatory T cells and activate chemokines, which sup-
press antitumor immunity [25, 26].
The use of cellular components of a systemic inflam-
matory response for predicting survival has received 
increased attention. A recent meta-analysis of 10 studies 
Table 2 Relationships between NLR–PLR and clinicopatho-
logic characteristics of 305 patients with stage I–II gastric 
cancer
mGPS modified glasgow prognostic score, PNI prognostic nutritional index, PLT 




Total 120 96 89
Age 0.026
 <60 years 77 50 41
 ≥60 years 43 46 48
Sex 0.735
 Male 81 65 56
 Female 39 31 33
Tumor location in the stomach 0.029
 Upper third 24 28 35
 Middle third 29 15 15
 Lower third 67 53 39
Tumor size <0.001
 <3 cm 77 48 31
 ≥3 cm 43 48 58
TNM stage 0.034
 IA 31 17 8
 IB 25 13 15
 IIA 16 18 16
 IIB 48 48 50
mGPS <0.001
 0 68 57 33
 1 10 11 23
 2 2 4 7
PNI <0.001
 0 120 94 68
 1 0 2 21
NLR–PLR <0.001
 0 114 70 26
 1 6 26 46
 2 0 0 17
Fig. 2 Kaplan–Meier overall survival curves for the patients with 
stage I–II gastric cancer after curative resection. a patients with either 
stage I or II gastric cancer. b only patients with stage I gastric cancer. 
c only patients with stage II gastric cancer. The survival curves show 
that the patients with an NLR–PLR score of 2 had significantly lower 
overall survival rates than the patients with an NLR–PLR score of 0 or 
1. NLR–PLR, the combination of neutrophil-to-lymphocyte ratio and 
platelet-to-lymphocyte ratio
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(involving a total of 2952 patients) found that a high NLR 
might be associated with poor prognosis for patients with 
gastric cancer [27]. In addition, a high PLR appeared to 
be associated with short progression-free and overall sur-
vival in the patients with advanced gastric cancer treated 
with chemotherapy [28].
We found that a higher NLR–PLR score was associ-
ated with larger tumor size and more advanced TNM 
stage. This finding supported those of previous stud-
ies, in which inflammation-based prognostic scores sig-
nificantly paralleled tumor progression [29–31]. In our 
study, Kaplan–Meier analysis showed that the NLR–PLR 
score was associated with OS (P < 0.001). The mean OS 
was shorter in stage I patients with a NLR-PLR score of 
2 (89 months) than in stage II patients with a NLR–PLR 
score of 0 (127 months). Although this difference was not 
significant (P  =  0.074), it was large enough to identify 
more patients at high risk undergoing curative resection 
than that afforded by TNM stage alone. In addition, mul-
tivariate analysis revealed that the NLR–PLR score was 
an independent predictor of OS. More importantly, the 
prognostic value of the NLR–PLR score was maintained 
in the patients with stage I (P < 0.001) and stage II can-
cers (P = 0.022).
We also found that several other established inflamma-
tion-based prognostic scores lacked independent prog-
nostic significance in multivariate analyses, although they 
were significantly associated with OS in univariate anal-
ysis. Obviously, in the context of stage I–II gastric can-
cer, the NLR–PLR score exerted more potent prognostic 
value than did the mGPS, PNI, and PLT–NLR. The area 
under the ROC curve was larger for the NLR–PLR score 
than for other prognostic scores. These results strongly 
support the prognostic value of the NLR–PLR score in 
the context of stage I–II gastric cancer patients undergo-
ing curative resection.
The major limitations of the present study were its ret-
rospective nature and the single-center experience. In 
Table 3 Univariate and multivariate Cox regression analyses of overall survival in 305 patients with stage I–II gastric can-
cer
mGPS modified glasgow prognostic score, PNI prognostic nutritional index, PLT platelet count, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
Characteristic Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Age (<60 vs. ≥60 years) 2.43 (1.49–3.96) <0.001 1.62 (0.91–2.89) 0.100
Sex (male vs. female) 0.61 (0.36–1.05) 0.075
Tumor location in the stomach (upper vs. middle vs. lower third) 0.59 (0.45–0.77) <0.001 0.77 (0.56–1.07) 0.119
Tumor size (<3 vs. ≥3 cm) 1.26 (0.78–2.01) 0.344
TNM stage (IA vs. IB vs. IIA vs. IIB) 1.60 (1.25–2.05) <0.001 1.36 (1.01–1.83) 0.041
mGPS (0 vs. 1 vs. 2) 1.86 (1.25–2.76) 0.002 1.24 (0.80–1.93) 0.345
PNI (0 vs. 1) 2.36 (1.21–4.62) 0.012 0.78 (0.31–1.93) 0.589
PLT–NLR (0 vs. 1 vs. 2) 1.40 (0.99–1.97) 0.057
NLR–PLR (0 vs. 1 vs. 2) 2.018 (1.50-2.72) <0.001 1.51 (1.02–2.24) 0.039
Fig. 3 Areas under the receiver operating characteristic curves pre-
dicting survival among 305 patients with stage I–II gastric cancer after 
curative resection. mGPS modified Glasgow prognostic score, PNI 
prognostic nutritional index, NLR–PLR the combination of neutrophil-
to-lymphocyte ratio and platelet-to-lymphocyte ratio
Table 4 Areas under  the receiver operating characteris-
tics (ROC) curve for  four inflammation-based prognos-
tic scores for  predicting overall survival in  305 patients 
with stage I–II gastric cancer after resection
mGPS modified glasgow prognostic score, PNI prognostic nutritional index, PLT 
platelet count, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte 
ratio
Prognostic score Area under the ROC curve (95% CI) P
mGPS 0.58 (0.49–0.68) 0.074
PNI 0.54 (0.44–0.63) 0.449
PLT–NLR 0.56 (0.47–0.66) 0.173
NLR–PLR 0.66 (0.57–0.74) 0.001
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addition, we lack data on disease-free survival, although 
OS is considered the standard indicator of cancer prog-
nosis [32]. However, our data were based on a large 
consecutive sample size and provided a valid basis to 
investigate the prognostic value of inflammatory mark-
ers. Furthermore, the surgical procedures (R0 resection 
plus D2 lymphadenectomy), laboratory tests, and patient 
follow-up were uniform during the entire study period.
Conclusions
We found that the NLR–PLR score predicted OS better 
than did other established inflammation-based prognos-
tic scores we tested in the patients with stage I–II gas-
tric cancer. This score may help clinicians identify the 
patients at a high risk of recurrence for rational therapy 
and closer follow-up.
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